Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Telix Pharmaceuticals ( (AU:TLX) ) has shared an update.
Telix Pharmaceuticals Limited announced the issuance of new unquoted equity securities as part of an employee incentive scheme. The issuance includes Deferred Share Rights for both US and ex-US employees and Performance Share Appreciation Rights for US employees, reflecting the company’s strategy to incentivize and retain talent, potentially impacting its operational efficiency and market competitiveness.
The most recent analyst rating on (AU:TLX) stock is a Buy with a A$36.00 price target. To see the full list of analyst forecasts on Telix Pharmaceuticals stock, see the AU:TLX Stock Forecast page.
More about Telix Pharmaceuticals
Telix Pharmaceuticals Limited operates in the biotechnology industry, focusing on the development and commercialization of diagnostic and therapeutic products using molecularly targeted radiation. The company primarily targets oncology and rare diseases, aiming to provide innovative solutions for cancer diagnosis and treatment.
Average Trading Volume: 1,612,530
Technical Sentiment Signal: Buy
Current Market Cap: A$8.81B
See more insights into TLX stock on TipRanks’ Stock Analysis page.